Basket Trial Evaluates Oral Ponatinib for Solid Tumors With Genomic Alterations
A phase 2 basket trial found oral ponatinib did not meet its primary endpoint in solid tumors with FGFR alterations, though several patients achieved disease control.
Read moreDetails



















